Objective: To compare the capacity of CD27, HLA-DR, CD38 and Ki-67 markers to characterize LTBI, active TB and patients who ended treatment and resolved TB. Methods: Blood was collected from 45 ...

Monoclonal antibodies included CD3, CD4, CD8, CD38, HLA-DR, CCR5, CXCR3, CD45, CD14, CD16, and CD49d conjugated to allophycocyanin (APC), phycoerythrin (PE) peridinin chlorophyll protein (PerCP), ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Mr. Higgins is a journalist based in New England. Before medical contrarianism became intrinsic to his identity, Dr. Mehmet Oz appeared motivated by curiosity rather than opportunism. Arriving at ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...